1Al-Khindi T,Macdonald RL,Schweizer TA.Cognitive and functional outcome after aneurysmal subarachnoid hemorrhage[J].Stroke.2010,41(8):519-36.
2Brines ML,Ghezzi P,Keenan S,et al.Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury[J].Proc Natl Acad Sci U S A.2000,97(19):10526-31.
3Ostrowski RP,Colohan AR,Zhang JH.Molecular mechanisms of early brain injury after subarachnoid hemorrhage[J].Neurol Res.2006,28(4):399-414.
4Sakowitz OW,Unterberg AW.Detecting and treating microvascular ischemia after subarachnoid hemorrhage[J].Curr Opin Crit Care.2006,12(2):103-11.
5Siren AL,Knerlich F,Poser W,et al.Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain[J].Acta Neuropathol.2001,101(3):271-6.
6Digicaylioglu M,Lipton SA.Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappa B signalling cascades[J].Nature.2001,412(6847):641-7.
7Ehrenreich H,Hasselblatt M,Dembowski C,et al.Erythropoietin therapy for acute stroke is both safe and beneficial[J].Mol Med.2002,8(8):495-505.
8Buemi M,Grasso G,Corica F,et al.In vivo evidence that erythropoietin has a neuroprotective effect during subarachnoid hemorrhage[J].Eur J Pharmacol.2000,392(1-2):31-4.
9Springborg JB,Moller C,Gideon P,et al.Erythropoietin in patients with aneurysmal subarachnoid haemorrhage:a double blind randomised clinical trial[J].Acta Neurochir(Wien).2007,149(11):1089-101;discussion 101.
